OncoLink

Print
 

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41

Presenter: Andre Robidoux
Affiliation: National Surgical Adjuvant Breast and Bowel Project and Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada

Background

Methods

Results

AC à WP + T (%)

AC à WP + L (%)

AC à WP + T + L (%)

p-value,
T vs. L

p-value,
T vs. T + L

Outcomes

pCR

52.5

53.2

62

0.990

0.095

pCR for HR+ subset

46.7

48

55.6

0.850

0.180

pCR for HR- subset

65.5

60.6

73

0.570

0.370

pCR breast and nodes

49.4

47.4

60.2

0.780

0.056

cCR

82

69.9

76.8

0.014

0.300

pCR low IHC, + FISH

41.7

60.9

25

0.310

0.330

pCR high IHC, + FISH

54.7

53.2

71

0.89

0.006

Toxicity

Grade 3 or 4 diarrhea

2

20

27

<0.001

< 0.001

Grade 3 or 4 left ventricular systolic dysfunction

4

4

2

0.490

Febrile neutropenia

4

2

5

0.530

Rise in ALT (liver enzymes), Grade 3

2

1

2

0.370

Treatment

Completion of therapy

78

68

63

0.010

Author's Conclusions

Scientific/Clinical Implications


OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.


Information Provided By: www.oncolink.org | © 2017 Trustees of The University of Pennsylvania